Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPsychiatry/Behavioral HealthAetna Eating Disorders Coverage Update | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0511

    Eating Disorders

    Customize your policy alerts

    Sign up for Aetna Policy 0511 alerts

    Get alerted when Policy 0511 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's coverage stance for assessment and treatment services for anorexia nervosa, bulimia nervosa, binge-eating disorder, and related eating disorders for enrolled members, and lists services considered medically necessary versus experimental/investigational/unproven.

    Policy Summary
    PayerAetna
    PolicyEating Disorders
    Policy CodePolicy 0511
    Change TypeNo material change
    Effective DateJun 11, 2001
    Last ReviewAug 4, 2026
    Next Review DateMay 27, 2027
    Key ActionObtain and document a complete medical and psychiatric evaluation, including relevant labs and ECG, when managing members with eating disorders.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2001policy effective year
    2026-08-04last review
    F50.xICD-10 ranges covered if criteria met
    manyprocedure/code examples listed
    multipletreatments listed as experimental

    Coverage Criteria and Policy Stance

    Medically Necessary — Assessment and Treatment

    Aetna considers the following services and procedures medically necessary for management of anorexia nervosa or bulimia nervosa when clinically appropriate:

    Medically necessary services list: Includes laboratory tests (albumin, prealbumin, CBC, electrolytes, BUN/creatinine, glucose, magnesium, phosphorus), bone density measurement (for evaluation of anorexic members), electrocardiography (ECG), liver function tests, LH/FSH/estradiol for women with amenorrhea or oligomenorrhea, complete medical evaluation, psychiatric/psychological consultation and testing, thyroid function testing (TSH), urinalysis, nutritional counseling, psychotherapy (cognitive behavioral therapy, dialectical behavior therapy, family-based psychotherapy, interpersonal psychotherapy, and psychodynamic psychotherapy), and enteral nutrition as a last resort for the treatment of anorexia nervosa.

    Experimental, Investigational, or Unproven — Assessment and Treatment

    The following are considered experimental, investigational, or unproven for diagnosis and treatment due to insufficient evidence:

    Experimental/Investigational list: Includes blood-based serotonergic biomarkers; brain imaging (MRI, PET, SPECT) for this indication; COMT Val158Met genotyping; EEG; ESR1 polymorphism testing; evaluation of genetic polymorphisms; gustatory function testing; gut microbiota evaluation and modulation; multi-sensory integration and olfaction evaluation; MC4R variant testing; Individual Optimal Nutrition (ION) analysis/profile; measurement of BDNF, betaine, hypothalamic neuropeptides, adiponectin, polyunsaturated fatty acids, serum cytokines, and serum zinc; proton MRS of neuro-metabolites; routine screening of asymptomatic adolescents/adults; 5-HTTLPR testing; acamprosate; acupuncture; bright light therapy (including for night eating syndrome); cannabinoids; chromium injection; deep brain stimulation; DHEA injection; digital single-session intervention (HOPE); electroconvulsive therapy; e-therapy; biofeedback/neurofeedback; food-specific inhibition training; ghrelin agonists; GLP-1 receptor agonists; imaginal exposure response prevention (I-ERP); intranasal naloxone; music therapy; neural therapy; oxytocin; relaxation therapy; repetitive transcranial magnetic stimulation (rTMS); Mandometer program; and transcranial direct current stimulation (tDCS).
    Policy Summary
    PayerAetna
    PolicyEating Disorders
    Policy CodePolicy 0511
    Change TypeNo material change
    Effective DateJun 11, 2001
    Last ReviewAug 4, 2026
    Next Review DateMay 27, 2027
    Key ActionObtain and document a complete medical and psychiatric evaluation, including relevant labs and ECG, when managing members with eating disorders.
    SourceLink
    On This Page
    Coverage Criteria and Policy StanceBilling Codes and Coding GuidanceProvider Responsibilities, Prior Authorization, and DocumentationBackground, Evidence Summaries, and DefinitionsLevel-of-Care and Setting CriteriaTreatment Modalities and Evidence-Based StatusVisit Limits, Duration, and Utilization NotesDefinitions and TerminologyPolicy Revision History

    Assessment, severity, and treatment sequencing

    Guideline-based assessment and treatment recommendations; coverage decisions tie to medical necessity criteria such as severity and need for multidisciplinary care.

    Initial assessment requirements: Initial evaluation must include screening for an eating disorder; assessment of height/weight history; eating and compensatory behaviors; psychosocial impairment; prior treatment and response; family history; and a comprehensive review of systems; weigh the patient and quantify eating and weight control behaviors.
    Initial physical and laboratory assessment: Physical exam should assess vital signs, height, weight, BMI (or age-appropriate BMI measures); obtain CBC and comprehensive metabolic panel including electrolytes, liver and renal tests; obtain ECG for restrictive disorders, severe purging, or when using QTc‑prolonging medications; include thyroid function testing (TSH).
    Indications for hospitalization: Severe medical instability such as ≤75% expected body weight, electrolyte imbalances, cardiac arrhythmias, profound hypoglycemia, impaired self-care, active suicidal ideation, or failure of outpatient treatment.
    Treatment sequencing: Outpatient nutritional rehabilitation and evidence‑based psychotherapy are first‑line for most patients; pharmacotherapy is adjunctive and disorder‑specific (e.g., fluoxetine for bulimia nervosa, lisdexamfetamine or antidepressants for binge‑eating disorder) and is not recommended as monotherapy for anorexia nervosa.

    Evidence summaries — no explicit coverage rules in this section

    Background evidence summaries; no explicit coverage rules in this section.

    Emerging/Experimental Interventions: Multiple interventions (bright light therapy, cannabinoids, deep brain stimulation, enteral nutrition, and other adjunctive or device‑based approaches) are described in the literature with variable, generally preliminary evidence; studies are often small, heterogeneous, and call for higher‑quality trials. No explicit coverage rules are provided here.

    Investigational/Insufficient Evidence — Coverage summary

    Summary coverage stance for interventions and tests discussed in background sections:

    Investigational or insufficient-evidence interventions: Ghrelin agonists (e.g., relamorelin) have limited short‑term RCT data showing decreased gastric emptying and trend to weight gain but lack long‑term safety/efficacy evidence; Mandometer residential treatment lacks well‑designed comparative trials and clinical value is unestablished; ION™ nutritional profiling lacks evidence of clinical value; multiple biomarker and genetic tests and other novel interventions remain preliminary and insufficient for routine coverage.

    Routine screening of asymptomatic adolescents and adults for eating disorders is listed as not covered (ICD-10: Z13.21) for indications in this clinical policy bulletin; screening without symptoms or clinical concern may therefore be denied as not medically necessary.

    The policy identifies specific device and neurostimulator CPT/HCPCS codes and related ICD-10 ranges used in the context of eating-disorder indications. Examples include neurostimulator programming and analysis codes (e.g., 95970–95976, 95983–95984, 96020), implantable generator and lead supply codes (e.g., C1767, C1778, C1816, C1883, C1897), and device supply ranges (L8680–L8683, L8685–L8689, L8695), as well as brain imaging and procedural codes referenced elsewhere (e.g., 70450–70553). The policy lists these codes to denote device-related services and to indicate when use for eating-disorder indications is considered not covered or investigational.

    Although the excerpt does not state an explicit exclusion line-item for deep brain stimulation (DBS), the document notes the lack of FDA approval for DBS in anorexia nervosa, small sample sizes, and limited randomized data—factors that may functionally exclude routine coverage absent documented investigational use and prior authorization.

    Background summaries in the policy describe numerous interventions as investigational or having uncertain clinical value. These include various device-based and biologic approaches (e.g., bright light therapy, cannabinoids, enteral nutrition practices, and commercial nutritional profiling), as well as genetic, gustatory, microbiota, and multi-sensory evaluations—most supported only by small, heterogeneous studies or preliminary reviews and therefore considered unproven for routine clinical use.

    The ION™ (Individual Optimal Nutrition) analysis/profile is described as a comprehensive commercial panel measuring multiple blood and urine nutritional markers, but the policy states there is a lack of evidence regarding its clinical value in diagnosing or evaluating patients with eating disorders and therefore it is considered unproven.

    The Mandometer residential program is described as a lengthy, residential treatment averaging about 12 months; the policy indicates that its clinical value has not been established and that effectiveness requires validation by well‑designed comparative trials, so routine coverage is unsupported without stronger evidence.

    The policy raises specific concerns about excitatory non‑invasive brain stimulation (NIBS) in anorexia nervosa: while single‑session rTMS reliably reduces food cravings, evidence for multi‑session excitatory NIBS in AN is controversial and there is a reported trend toward iatrogenic weight loss, suggesting potential contraindication or unclear safety/efficacy in this population.

    Clinical practice guidelines and the policy emphasize that transcranial magnetic stimulation (TMS) is experimental or adjunctive for eating disorders and should not replace nutritional rehabilitation or evidence‑based psychotherapy; TMS consideration should follow optimization of standard treatments.

    The policy lists numerous specific procedures and codes related to neurostimulation, brain imaging, genetic/molecular testing, relaxation therapy, and other tests as investigational or not covered for the eating‑disorder indications addressed in this bulletin. Examples cited include TMS and ECT procedure codes (90867–90869, 90870), brain imaging codes (70450–70553), and molecular/genetic testing codes (81403), which are identified in the document as associated with experimental or not medically necessary services for these indications.

    Use of the listed neurostimulator and accessory device HCPCS/CPT codes (for example C1767, C1778, L8680–L8689 and related programming/analysis codes) for the eating‑disorder indications in this clinical policy bulletin is designated as not covered when used for those indications.

    Several complementary and alternative approaches are described but supported only by very low‑quality evidence; for example, the acupuncture at Sifeng trials for pediatric anorexia include many small RCTs with high or unclear risk of bias, and authors rate the overall certainty of evidence as extremely poor despite positive signals in some outcomes.

    In a small clinical trial of ghrelin administration in patients with anorexia nervosa, ghrelin did not significantly affect appetite and investigators concluded that ghrelin is unlikely to be effective as a single appetite‑stimulatory treatment, limiting support for routine use.

    The policy groups a range of interventions and tests as lacking sufficient evidence for routine clinical use—this includes the ION™ nutritional profiling panel, the Mandometer residential program, ghrelin agonists and other novel pharmacologic agents, and various experimental neuromodulation or sensorimotor evaluations—pending well‑designed randomized trials or higher‑quality comparative data.

    Several interventions discussed in the background are supported only by very small case reports or heterogeneous small studies; examples noted in the policy include neural therapy case reports for bulimia and small, variable music‑based intervention studies, which lack sufficient size or consistency to establish generalizable clinical benefit.

    Billing Codes and Coding Guidance

    Covered CPT Codes (selection)CPTCovered
    76977Ultrasound bone density measurement and interpretation, peripheral site(s), any method.
    77078Computerized tomography, bone mineral density study, 1 or more sites.
    77080Dual energy x-ray absorptiometry (DXA), bone density study, 1 or more sites.
    80047Basic metabolic panel (Calcium, ionized).
    80048Basic metabolic panel (Calcium, total).
    80050General health panel.
    80053Comprehensive metabolic panel.
    80076Hepatic function panel.
    81000Urinalysis.
    82040Albumin; serum, plasma or whole blood.
    1–10 of 21
    1/3
    HCPCS Codes Covered if Selection Criteria Are MetHCPCSCovered
    B4034Enteral feeding supply kit.
    B4102Enteral formula.
    B9002Enteral nutrition infusion pump, any type.
    S9340Home therapy; enteral nutrition, enteral nutrition via gravity, per diem.
    ICD-10 Codes Covered if Selection Criteria Are MetICD-10Covered
    F50.00 - F50.029Anorexia nervosa.
    F50.20 - F50.25Bulimia nervosa.
    F50.810 - F50.819Binge eating disorder.
    F50.82Avoidant/restrictive food intake disorder.
    R63.0Anorexia.
    Device and neurostimulation CPT/HCPCS codes mentionedmixed
    95970Neurostimulator-related code (device status/programming) - as listed in policy
    95971Simple spinal cord or peripheral neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming
    95976Electronic analysis of implanted neurostimulator pulse generator/transmitter with simple cranial nerve programming
    95983Electronic analysis of implanted neurostimulator pulse generator/transmitter with brain neurostimulator programming, first 15 minutes
    95984Electronic analysis of implanted neurostimulator pulse generator/transmitter with brain neurostimulator programming, additional 15 minutes
    96020Neurofunctional testing selection and administration during noninvasive imaging functional brain mapping
    C1767Generator, neurostimulator (implantable), nonrechargeable
    C1778Lead, neurostimulator (implantable)
    C1816Receiver and/or transmitter, neurostimulator (implantable)
    C1883Adaptor/extension, pacing lead or neurostimulator lead (implantable)
    1–10 of 14
    1/2
    ICD-10 ranges referencedICD-10
    F50.00 - F50.029Anorexia nervosa (ICD-10 range) — listed among ICD-10 codes not covered for indications in CPB
    F50.20 - F50.25Bulimia nervosa (ICD-10 range)
    Procedures/Drugs — unspecified codesmixed
    not listedNo specific CPT/HCPCS/ICD codes are provided for relamorelin or ghrelin agonist administration in this section.
    Laboratory panels — unspecified codingmixed
    not listedION™ panel — commercial laboratory panel; no specific CPT/HCPCS codes specified in document.
    inv-28: Bone density measurement — key-value note for use in evaluation of anorexic members
    Recommended testsDXA (77080/77081), peripheral ultrasound bone density (76977), or CT bone mineral density study (77078) are listed as bone density measurements for evaluation of anorexic members.
    Context of useBone density measurement is included among medically necessary assessment tests for anorexia nervosa when clinically appropriate (to evaluate low bone mass/osteopenia/osteoporosis).
    Related labsConsider with other baseline assessments such as CBC, electrolytes, calcium, magnesium, phosphorus, albumin/prealbumin, liver function, and TSH.
    inv-29: Severe low body weight threshold for hospitalization — clinical threshold key/value
    Hospitalization thresholdSevere low body weight defined as 75% or less of expected body weight (indicator for inpatient/hemodynamic stabilization).
    Other indications for hospitalizationElectrolyte imbalances, cardiac arrhythmias, profound hypoglycemia, impaired self-care, active suicidal ideation, or failure of outpatient treatment.
    Bulimia-specific notePatients with bulimia rarely require hospitalization unless binge–purge cycle causes severe metabolic disturbances or suicidal depression.
    inv-30: Anorexia diagnostic BMI threshold (consideration) — BMI ≤ 17.5 kg/m²
    Consideration thresholdBMI ≤ 17.5 kg/m² is noted as a threshold at which an anorexia nervosa diagnosis should be considered (particularly in young women).
    Diagnostic contextApplied with symptoms such as amenorrhea, refusal to maintain minimally normal weight, and distorted body image; similar considerations apply to males with unexplained weight loss.
    Relation to expected weightPolicy also references <85% expected body weight as a classical descriptor of AN; BMI ≤17.5 is an additional consideration for diagnosis.

    Provider Responsibilities, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required for home enteral nutrition when selection criteria apply

    Certain home enteral nutrition and enteral formula HCPCS codes are covered if selection criteria are met and may require prior authorization under this policy; providers should obtain prior authorization when billing codes such as S9340–S9343, B4034–B4036, B4102–B4162, and B9002 are used for home enteral nutrition services.

    • HCPCS codes referenced: S9340–S9343, B4034–B4036, B4102–B4103, B4149–B4162, B9002
    Billing Rule

    Use listed CPT/HCPCS device and procedure codes and note coverage designations

    The policy lists specific CPT/HCPCS codes for device-based and neurostimulation procedures and notes some codes are designated not covered for the indications in this CPB; use the listed codes when requesting authorization and beware of not‑covered designations.

    • Device/neurostimulator codes cited include 95970–95976, 95983–95984, 96020 and HCPCS C1767, C1778, C1816, C1883, C1897, E0745, L8680–L8689, L8695.
    • HCPCS enteral/home nutrition codes are listed separately (see enteral nutrition section).
    Prior Authorization

    Prior authorization and detailed clinical data required for DBS and other invasive experimental procedures

    Invasive or experimental procedures such as deep brain stimulation (DBS) generally require prior authorization with submission of patient‑level data demonstrating treatment‑refractory status, prior therapies tried, and rationale for the chosen stimulation target.

    • DBS described as experimental/under study; systematic reviews included patient‑level data and highlighted safety/adverse event concerns and small sample sizes.
    • Prior authorization should include documentation of prior attempts and rationale for DBS target selection.
    Note

    Background evidence summaries do not substitute for prior‑authorization rules

    Background and evidence summary sections do not by themselves state specific prior authorization requirements; they summarize evidence that may inform coverage determinations but do not replace administrative PA rules.

    • Evidence summaries in background may influence but do not specify PA code or process.
    • Administrative prior‑authorization requirements are addressed elsewhere in the policy.
    Prior Authorization

    Prior authorization likely required for investigational interventions (relamorelin, ION™, Mandometer)

    Interventions characterized as investigational or with insufficient evidence (for example, relamorelin, the ION™ panel, and the Mandometer residential program) may require prior authorization with supporting clinical rationale and documented trial data before coverage is considered.

    • Relamorelin (ghrelin agonist) studied in small RCTs; long‑term safety/efficacy not established.
    • ION™ analysis/profile lacks evidence of clinical value.
    • Mandometer residential program clinical value not established; may be considered investigational.
    Prior Authorization

    Require prior authorization and clinical rationale for novel neuromodulation

    Novel neuromodulation treatments (multi‑session rTMS, tDCS, and similar) remain investigational with mixed evidence; prior authorization should require documentation of rationale, informed consent, and evidence of prior standard therapies.

    • Multi‑session rTMS/tDCS evidence is preliminary and mixed; excitatory NIBS in anorexia may be contraindicated.
    • PA should document prior attempts at nutritional rehabilitation and evidence‑based psychotherapy, rationale for neuromodulation, and monitoring plans.
    Prior Authorization

    Prior authorization must justify TMS as adjunctive/experimental therapy

    When TMS is considered for eating disorders it should be treated as adjunctive/experimental; prior authorization should request justification that TMS is being used as adjunctive treatment and documentation of failure or intolerance of established treatments, plus a monitoring plan for outcomes and adverse events.

    • Guidelines state TMS is not an established treatment and should not replace nutritional rehabilitation or evidence‑based psychotherapy.
    • PA should include prior treatment history, rationale for TMS, stimulation protocol/site, and monitoring plan.
    Note

    No specific PA codes listed in this excerpt — follow plan PA processes

    This administrative excerpt does not state specific prior authorization code requirements; providers should follow plan‑level PA processes and use the policy’s listed codes when applicable.

    • The CPB is an administrative aid and does not list a separate PA code table in this excerpt.
    • Follow member plan provisions and Aetna PA procedures for submission.
    Step Therapy

    No explicit step‑therapy algorithm provided in this excerpt

    No explicit step‑therapy algorithm is specified in this portion of the document; the policy does not define a formal step‑through sequence here.

    Note

    Document sequencing: pharmacotherapy is adjunctive (fluoxetine for BN; lisdexamfetamine for BED)

    Pharmacotherapy is described as adjunctive to nutritional rehabilitation and psychotherapy; fluoxetine is recommended for bulimia nervosa (e.g., 60 mg) and lisdexamfetamine is an FDA‑approved option for binge‑eating disorder.

    • Fluoxetine recommended for BN (60 mg daily) as first‑line pharmacotherapy.
    • Lisdexamfetamine is an option for BED; medications are adjunctive and not first‑line for AN.
    Step Therapy

    CBT is guideline‑preferred first‑line psychotherapy before alternatives

    Practice guidelines and major reviews recommend CBT as first‑line psychotherapy for bulimia and BED; payers may expect a trial of CBT before covering adjunctive or alternative psychotherapies in many cases.

    • DBT is considered adjunctive/alternative and has not shown superiority to CBT in systematic reviews; CBT remains first‑line.
    • Document trials of CBT when seeking coverage for alternative psychotherapies.
    Step Therapy

    No step‑therapy rules described; ghrelin agonists are investigational

    No formal step‑therapy requirements are described in these background sections; ghrelin agonists and similar agents are noted as investigational and lack sufficient evidence to define sequencing rules.

    • Ghrelin administration did not significantly affect appetite in a small trial and relamorelin has limited short‑term data.
    • No step‑therapy sequencing is specified for these agents in the excerpt.
    Step Therapy

    No step‑therapy rules specified in background sections

    Background sections do not specify step‑therapy rules; the document states no formal step‑therapy algorithms are provided in this excerpt.

    Step Therapy

    Require trial of lower‑intensity interventions (guided self‑help/psychotherapy) before higher‑intensity BED treatments

    For BED, evidence supports guided self‑help and certain pharmacotherapies; consider requiring trials of lower‑intensity guided self‑help or psychotherapy before authorizing higher‑intensity pharmacotherapy or surgical interventions.

    • Guided self‑help showed benefit for BED in referred populations.
    • Lisdexamfetamine and topiramate reduced BED symptom severity but have associated harms and require monitoring.
    Step Therapy

    Neuromodulation only after optimization of nutrition and evidence‑based psychotherapies

    Neuromodulation (including TMS) should be considered only after optimization of nutritional rehabilitation and evidence‑based psychotherapies; documentation of prior optimization is expected when seeking authorization.

    • Guidelines emphasize TMS should not replace nutritional rehabilitation or evidence‑based psychotherapy.
    • PA/authorization should show attempts to optimize nutrition and psychotherapy prior to neuromodulation.
    Step Therapy

    No formal step‑therapy protocol specified in this excerpt

    Reiterating the document’s content, no formal step‑therapy protocol is specified within this excerpt; providers must follow plan‑specific step rules if present elsewhere.

    Documentation Required

    Document complete medical evaluation and recommended laboratory testing

    Clinical documentation must include a complete medical history and physical examination and relevant laboratory testing (e.g., CBC, electrolytes, liver function tests, TSH, ECG) when managing anorexia nervosa or bulimia nervosa.

    • Document CBC and comprehensive metabolic panel including electrolytes, liver and renal tests.
    • Obtain ECG for restrictive disorders, severe purging, or QTc‑prolonging medications.
    Documentation Required

    Document comprehensive initial psychiatric and physical evaluation including height/weight history

    Initial psychiatric and physical evaluations should document height/weight history, patterns of restrictive and binge/purge behaviors, compensatory behaviors, psychosocial impairment, prior treatment response, and a comprehensive review of systems as part of the initial workup.

    • Record maximum/minimum weight, recent weight changes, and quantify eating/weight control behaviors.
    • Identify co‑occurring psychiatric and medical conditions and include a comprehensive review of systems.
    Documentation Required

    Document indication, malnutrition evidence, feeding method and monitoring for enteral nutrition

    For enteral nutrition (nasogastric feeding) document the indication for weight restoration, evidence of malnutrition or refractory oral intake, details of the feeding method and monitoring (including prophylactic electrolyte/phosphate supplementation where used), and whether care is inpatient versus outpatient.

    • Document objective evidence of inadequate oral intake and weight restoration goals.
    • Include details of NG feeding method, monitoring plans, and any prophylactic electrolyte management.
    Documentation Required

    Provide clear clinical rationale and document study limitations when using limited‑evidence interventions

    When submitting evidence or studies for limited‑evidence interventions, note methodological limitations (small samples, lack of dietary control, female‑only cohorts); include a clear clinical rationale tied to member‑level data when using such interventions.

    • Describe study limitations if relying on literature to support coverage requests.
    • Provide member‑specific clinical justification beyond limited studies.
    Documentation Required

    Document baseline diagnosis, BMI, gastric emptying testing, and monitoring for ghrelin agonist use

    For trials or off‑label use of ghrelin agonists (e.g., relamorelin) document DSM‑5 diagnosis, baseline weight/BMI, gastric emptying testing if used (GEBT), and monitoring of weight change and adverse effects during treatment.

    • Include baseline BMI and GEBT results when used to support relamorelin use.
    • Monitor and record weight change and any adverse events during therapy.
    Documentation Required

    Document diagnosis, setting, outcomes, and concurrent treatments for I‑ERP programs

    For I‑ERP programs record the diagnosis, treatment setting (inpatient vs outpatient), concurrent treatments, pre‑ and post‑intervention outcome measures (e.g., EDE‑Q, anxiety/depression scales), and follow‑up plans.

    • Document outcome measures and follow‑up; note that existing I‑ERP evidence is pilot‑level and often adjunctive to inpatient care.
    • Specify program structure and concurrent therapies.
    Documentation Required

    Document prior trials and monitor adverse effects for BED pharmacotherapies

    When using pharmacotherapies for BED (e.g., lisdexamfetamine or topiramate), document prior trials, rationale for selection, and actively monitor for known adverse effects (dry mouth, headache, insomnia for lisdexamfetamine; paresthesia, taste perversion, confusion for topiramate).

    • Record prior psychotherapy/guided self‑help trials and justify medication initiation.
    • Monitor and document adverse effects reported in RCTs.
    Documentation Required

    Document rationale, stimulation parameters, and monitoring when using TMS/neuromodulation

    Clinical documentation for neuromodulation (including TMS) should state that TMS is being used adjunctively/experimentally, include the rationale and targeted symptoms, specify stimulation site/protocol and parameters, and describe plans for monitoring adverse events and outcomes.

    • Include stimulation protocol, site (e.g., dorsolateral prefrontal cortex), session duration and frequency.
    • Document informed consent and plan for outcome monitoring and adverse event surveillance.
    Documentation Required

    Providers must follow plan provisions and monitor CPB updates

    Treating providers are responsible for medical advice and treatment of members; Clinical Policy Bulletins may be updated and are a partial description of plan benefits—verify plan provisions and follow any updated CPB guidance.

    • CPBs do not constitute a contract; coverage outcomes are determined by plan provisions.
    • Providers must follow current CPB updates and member benefit details.
    Denial Risk

    Denial risk when billing codes for experimental/unproven services

    Use of CPT/HCPCS codes for services explicitly listed as experimental/investigational or not covered (for example brain imaging, EEG, rTMS, ECT, fecal microbiota procedures, certain molecular/genetic tests) may trigger claim denials; verify coverage status before billing.

    • Examples of codes/services at risk: brain imaging (70450–70553), EEG, 90867–90869 (TMS) and 90870 (ECT), 81403 (molecular pathology).
    • Confirm coverage or obtain PA and provide supporting clinical documentation to mitigate denial risk.
    Denial Risk

    Device/neurostimulator codes and certain ICD‑10 ranges are designated not covered for CPB indications

    Specific HCPCS/CPT device and implantable neurostimulator codes and related ICD‑10 ranges are listed as not covered for indications in this CPB; billing these codes for the listed eating‑disorder indications risks denial unless an approved exception/PA is obtained.

    • HCPCS device codes not covered include C1767, C1778, C1816, C1883, C1897, E0745, L8680–L8689, L8695.
    • ICD‑10 ranges cited as not covered for CPB indications include F50.00–F50.029 and F50.20–F50.25.
    Denial Risk

    DBS for anorexia nervosa has limited evidence and safety concerns—denial risk without strong documentation

    Deep brain stimulation for anorexia nervosa is experimental and studied in small cohorts with reported adverse events (including a serious seizure); limited randomized data and safety concerns may lead to medical necessity denials or requests for additional documentation.

    • DBS studies pooled 36 patients across 11 studies; adverse events included a seizure and other surgical complications.
    • Provide robust patient‑level evidence of refractory illness and justification to avoid denial.
    Note

    Background evidence summaries do not mandate specific authorization actions

    Background sections do not mandate specific authorization actions; they summarize evidence and research gaps that may inform but do not dictate coverage or PA outcomes.

    Denial Risk

    ION™ nutritional profiling lacks evidence—coverage may be denied as unproven

    The ION™ (Individual Optimal Nutrition) analysis/profile lacks evidence of clinical value in eating disorders; ordering or billing for this panel without supporting evidence may be at risk for denial as medically unproven.

    • ION™ measures multiple blood and urine nutritional markers but clinical utility in EDs is unproven.
    • Provide strong clinical justification and prior evidence if requesting coverage.
    Denial Risk

    Mandometer residential program is investigational—coverage may be denied without strong evidence

    The Mandometer residential program is investigational with insufficient well‑designed comparative trials to establish clinical value; coverage may be denied absent strong comparative evidence and clear medical necessity.

    • Program duration and remission claims derive largely from non‑randomized or small studies; randomized evidence is limited.
    • Document comparative benefit and clinical necessity when requesting coverage for residential Mandometer treatment.
    Denial Risk

    Residential/PHP continued‑stay coverage may be limited by lack of long‑term controlled evidence

    Residential and PHP settings show short‑term improvements at discharge but lack controlled long‑term trial evidence and have high loss to follow‑up; continued‑stay or ongoing coverage decisions should document objective clinical response and nutritional markers.

    • Few controlled long‑term outcome studies exist; document response at discharge and objective markers to support continued coverage.
    • High drop‑out rates in studies complicate long‑term benefit claims.
    Denial Risk

    Using TMS outside established indications requires clear justification to avoid denial

    TMS is described as experimental/adjunctive and not an established treatment for eating disorders; use of TMS outside established indications should be justified in the medical record to reduce denial risk.

    • Guidelines advise TMS should not replace nutritional rehabilitation or evidence‑based psychotherapy.
    • Document rationale, prior therapy failures, and monitoring plans when using TMS.
    Note

    CPBs are administrative guides; final coverage is determined by plan provisions

    Clinical Policy Bulletins assist in administering plan benefits and provide only a partial description of benefits; coverage determinations are made according to the member's plan provisions and are not guaranteed by the CPB.

    Background, Evidence Summaries, and Definitions

    This policy addresses major eating‑disorder diagnoses including anorexia nervosa and bulimia nervosa and provides an overview of management: guideline‑based assessment (medical history, weight/BMI, laboratory testing, ECG when indicated), outpatient first‑line care with nutritional rehabilitation and psychotherapy (CBT, family‑based therapy, interpersonal therapy), pharmacotherapy as adjunctive where evidence supports it (e.g., fluoxetine for bulimia, lisdexamfetamine for binge‑eating disorder), and escalation to enteral nutrition or higher levels of care for severe medical instability. The background sections also summarize evidence gaps for many novel and device‑based interventions and stress the need for multidisciplinary care and documentation when invasive or investigational therapies are considered.

    inv-66: Eating disorder diagnostic categories (ICD-10) — list of diagnostic categories as key-values
    Anorexia nervosa (ICD-10)F50.00 - F50.029
    Bulimia nervosa (ICD-10)F50.20 - F50.25
    Binge-eating disorder (ICD-10)F50.810 - F50.819
    Avoidant/restrictive food intake disorder (ICD-10)F50.82
    Symptom codeR63.0 (Anorexia) — coded for clinical presentations when applicable.
    inv-67: Anorexia nervosa — definition/key diagnostic features
    Core definitionRefusal to maintain a minimally normal body weight (e.g., weight <85% of expected), distorted body image, and intense fear of weight gain; amenorrhea historically described in post-menarcheal females.
    Diagnostic cluesConsider diagnosis with BMI ≤17.5 kg/m² or unexplained weight loss; often begins in adolescence/young adulthood and predominantly affects females (~90% of cases).
    Medical complicationsAssociated with high mortality (lifetime mortality 15–20%) and medical complications across cardiovascular, endocrine, GI, and neurologic systems.
    inv-68: Bulimia nervosa — definition/key diagnostic features
    Core definitionRecurrent episodes of binge eating followed by inappropriate compensatory behaviors (purging, restriction, excessive exercise), typically occurring at least twice weekly for three months; patients often maintain normal weight.
    Clinical featuresExcessive preoccupation with weight and shape; associated metabolic disturbances (e.g., electrolyte imbalances) when purging is frequent.
    Severity and hospitalizationHospitalization for BN is rare unless severe metabolic derangements, progression to anorexia, or suicidal depression occur.
    inv-69: Night eating syndrome — definition/key diagnostic features
    DefinitionNight eating syndrome (NES) is a delayed pattern of food intake with recurrent nocturnal eating and/or excessive consumption after the evening meal.
    Clinical associationsNES is associated with sleep disturbance, obesity risk, and other psychiatric comorbidities; may be underrecognized in clinical settings.
    Assessment toolsClinical assessment tools such as the Night Eating Questionnaire may assist in diagnosis and evaluation.
    inv-70: Bright light therapy — definition and context
    DefinitionBright light therapy is a non-invasive biological intervention targeting circadian features of eating disorders, studied for effects on binge-eating and night-eating patterns.
    Evidence summarySystematic review identified 14 studies meeting inclusion; short-term improvements in disordered eating behaviors and mood were reported but long-term efficacy and placebo-controlled data are limited.
    Clinical implicationConsidered experimental/adjunctive in the policy background pending further high-quality trials.
    inv-71: Deep brain stimulation (DBS) — definition and investigational context
    DefinitionDeep brain stimulation (DBS) is surgically implanted electrical stimulation of specific brain targets (e.g., subcallosal cingulate) investigated experimentally for treatment‑refractory anorexia nervosa.
    Evidence and safetySmall pilot/observational studies (e.g., 6 patients in Lipsman et al.) reported some improvements in BMI and mood but also serious adverse events (one seizure) and overall limited, nonrandomized data.
    Policy stanceDBS is described as experimental/under study; lack of randomized sham‑controlled trials and safety concerns may trigger denial without strong justification and prior authorization.
    inv-72: Enteral nutrition (NG feeding) — definition and use in weight restoration
    DefinitionEnteral nutrition (nasogastric feeding) is tube feeding used to facilitate weight restoration in malnourished patients with anorexia nervosa.
    EfficacySystematic reviews report NG feeding commonly increases short-term weight gain (often >1 kg/week) and higher caloric intake versus oral-only controls in many studies.
    Safety and monitoringMost evidence derives from in-hospital use with prophylactic phosphate supplementation reported and low rates of re-feeding hypophosphatemia; documentation should include indication, malnutrition evidence, and monitoring details.
    inv-73: Enteral Nutrition (EN) — short notation
    Short notationEnteral Nutrition (EN) — tube-based nutritional support used for refeeding in AN/selected BN cases.
    Clinical noteEN lacks standardized protocols and long-term outcome consistency; used as essential, sometimes life‑saving, intervention in severe cases.
    inv-74: Genetic polymorphisms for BED — summary definition
    DefinitionGenetic polymorphisms for BED refers to candidate genetic variants studied for association with binge‑eating disorder; multiple polymorphisms have been investigated but findings remain preliminary and heterogeneous.
    Examples studiedPolymorphisms assessed include 5-HTTLPR, Taq1A (ANKK1/DRD2), A118G (OPRM1), Val158Met (COMT), MC4R variants, BDNF (rs6265), and GHRL Leu72Met among others — overall evidence insufficient for clinical use.
    Policy implicationGenetic testing/polymorphism panels are considered investigational/unproven for routine diagnosis or management of BED in this policy.
    inv-75: Ghrelin agonists — definition and intended effects
    DefinitionGhrelin agonists are pharmacologic agents that stimulate the ghrelin receptor aiming to increase appetite and affect gastric emptying and neuroendocrine responses (e.g., relamorelin).
    Trial dataRelamorelin RCT in women with AN (n=22) showed significantly shorter gastric emptying time and a trend toward weight gain after 4 weeks; older ghrelin infusion trials did not significantly increase appetite.
    Policy noteGhrelin agonists are investigational/insufficient evidence for routine use pending long-term safety and efficacy data.
    inv-76: Imaginal Exposure Response Prevention (I-ERP) — definition and program description
    DefinitionImaginal Exposure Response Prevention (I-ERP) is a behavioral program adapted for adolescents that uses imaginal exposure to fears of normal body weight with response prevention techniques, delivered in a brief group format as an adjunct to inpatient care.
    EvidencePilot study (n=19) showed reduced anxiety related to weight/shape but no significant change in eating disorder psychopathology; further controlled trials are needed.
    DocumentationPolicy recommends recording diagnosis, setting, concurrent treatments, and pre/post outcome measures when I-ERP is used in trials or programs.
    inv-77: ION™ (Individual Optimal Nutrition) analysis — definition and components
    DefinitionION™ (Individual Optimal Nutrition) analysis is a commercial panel measuring multiple blood and urine nutritional markers (amino acids, fatty acids, minerals, organic acids, vitamins) marketed to evaluate functions impacting mental and physical well‑being.
    EvidencePolicy states there is a lack of evidence regarding the clinical value of the ION profile in the diagnosis and evaluation of eating disorders.
    Policy implicationClaims for ION™ analysis may be at risk for denial as medically unproven for eating disorder indications.
    inv-78: Eating disorders (EDs) — broad definition
    DefinitionEating disorders are psychiatric conditions with persistent disturbances in eating or related behaviors that impair physical or psychosocial functioning, including AN, BN, BED, and related disorders.
    Multifactorial etiologyInfluenced by biological, psychological, and social factors; management commonly includes nutritional rehabilitation, psychotherapy, and sometimes pharmacotherapy within multidisciplinary care.
    Potential complicationsCan result in serious medical complications across multiple organ systems and increased mortality risk.
    inv-79: SCOFF questionnaire — screening tool performance metrics
    Tool descriptionSCOFF questionnaire is a screening tool for eating disorders; at a cut-point ≥2 it demonstrated pooled sensitivity 84% and specificity 80% in adults.
    Performance contextBased on a systematic review of screening test accuracy studies included in USPSTF-related analysis (10 studies, n=3,684 adults).
    Screening caveatUSPSTF concluded evidence insufficient to recommend routine screening in asymptomatic adolescents/adults; policy lists routine screening (Z13.21) as not covered for asymptomatic populations.
    inv-80: 5-HTTLPR — genetic polymorphism definition and relevance
    Definition5-HTTLPR is a functional polymorphism of the serotonin transporter gene (serotonin transporter-linked polymorphic region) studied for association with eating disorders.
    Evidence summaryMeta-analyses and pooled studies (including BIO.VE.D.A.) found no consistent association between 5-HTTLPR and EDs; results have been conflicting and not supportive of routine clinical testing.
    Policy stanceTesting for 5-HTTLPR is considered investigational/unproven for clinical management of eating disorders in this policy context.
    inv-81: BED and LOC eating (youth) — definition and trial context
    DefinitionBED and LOC eating (youth) refers to binge eating disorder and loss-of-control eating in individuals under age 20 assessed in trials of talking therapies.
    EvidenceScoping review identified 10 quantitative studies (8 RCTs, 2 case series) with ~2,400 young people showing CBT, DBT, IPT, FB-IPT and other modalities associated with reductions in binge/LOC episodes.
    Clinical implicationTalking therapies are primary treatments for BED/LOC in youth; more research is needed to strengthen evidence base.
    inv-82: Transcranial Magnetic Stimulation (TMS) — definition and investigational context
    DefinitionTranscranial Magnetic Stimulation (TMS) is a noninvasive neuromodulatory technique targeting cortical areas (commonly dorsolateral prefrontal cortex) investigated as an experimental/adjunctive treatment for eating disorders.
    Evidence and limitationsSystematic reviews and trials report mixed effects on psychopathology, craving, mood, and weight outcomes; evidence limited by small sample sizes, heterogeneous protocols, and short follow-up.
    Policy guidanceTMS is not an established treatment and should not replace nutritional rehabilitation or evidence‑based psychotherapy; prior authorization and strong documentation are advised if considered as adjunctive therapy.

    Level-of-Care and Setting Criteria

    Residential / Partial Hospitalization (PHP)

    Residential / PHP evidence caveat: Higher levels of care (residential or partial hospitalization) may be required for reversing malnutrition or when outpatient care is insufficient; however, long‑term comparative evidence is limited and loss to follow‑up is substantial, so continued‑stay decisions should document objective clinical response and nutritional markers.

    Outpatient/Youth talking therapies

    Youth talking therapies: Talking therapies studied in youth include CBT (group and individual), DBT, IPT, family‑based IPT, and schema therapy; limited trials show reductions in binge episodes and loss‑of‑control eating, but sample sizes are often small and outcomes heterogeneous.

    Treatment Modalities and Evidence-Based Status

    Psychotherapy

    Psychotherapy services are considered medically necessary when delivered as eating disorder–focused treatments.

    Psychotherapy modalities: Eating disorder‑focused psychotherapies considered medically necessary include cognitive behavioral therapy (CBT), family‑based psychotherapy, interpersonal psychotherapy (IPT), psychodynamic psychotherapy, and DBT when clinically indicated (e.g., prominent emotion dysregulation or comorbid BPD); psychotherapy should be part of a multidisciplinary treatment plan.

    Device-based neuromodulation and procedural therapies

    Device-based neuromodulation and procedural therapies are generally considered investigational or unproven for eating disorder indications unless robust supporting evidence is provided.

    Device/procedural modalities considered investigational: Includes rTMS/TMS, tDCS, deep brain stimulation (DBS), electroconvulsive therapy (ECT), implanted neurostimulators and associated device codes, fecal microbiota procedures, and other device‑based interventions listed as experimental in this policy; these interventions require strong supporting evidence and prior authorization when requested for investigational use.

    Psychotherapy

    Eating disorder–focused psychotherapies are first‑line treatments and should be prioritized in coverage decisions.

    Psychotherapy as core treatment: Outpatient psychotherapy (CBT, family‑based therapy, IPT, psychodynamic approaches) is first‑line for most eating disorders and should be delivered with nutritional rehabilitation and medical monitoring as needed; psychosocial and caregiver involvement should be documented.

    Medication therapy

    Pharmacotherapy is adjunctive and disorder‑specific.

    Medication therapy: Medication should be used as adjunct to nutritional rehabilitation and psychotherapy: fluoxetine 60 mg recommended for bulimia nervosa; lisdexamfetamine or antidepressants for binge‑eating disorder; medications have limited efficacy in anorexia nervosa and are not primary treatments.

    Other biological/behavioral interventions

    Other biological or behavioral adjuncts have preliminary data but lack definitive evidence for routine coverage.

    Adjunctive/experimental therapies: Bright light therapy, melatonergic medications, topiramate for night‑eating phenotypes, and feedback‑based therapies (biofeedback/neurofeedback) have preliminary evidence; larger, controlled trials are needed before routine coverage can be supported.

    Dialectical Behavior Therapy (DBT)

    DBT may be used as an alternative or adjunctive psychotherapy in selected patients.

    DBT use: DBT has been adapted for binge‑spectrum disorders and may be considered for patients with prominent emotion dysregulation or comorbid borderline personality disorder; evidence shows within‑group improvements but not consistent superiority over CBT.

    Bright light therapy

    Bright light therapy is experimental with limited short‑term effects noted in small studies.

    Bright light therapy evidence: Systematic reviews identify small short‑term improvements in disordered eating behaviors and mood for circadian‑related eating disorder presentations, but placebo‑controlled and long‑term data are lacking.

    Deep brain stimulation (DBS)

    Deep brain stimulation has been studied in small, treatment‑refractory cohorts and remains investigational.

    DBS evidence and limitations: DBS for chronic, treatment‑refractory anorexia nervosa has shown some improvements in BMI and mood in small case series and pilot studies; systematic reviews identify heterogeneity of targets and small sample sizes (e.g., pooled 36 patients), and randomized sham‑controlled data are lacking; adverse events including seizures have been reported.

    e-therapy, biofeedback/neurofeedback, behavioral inhibition training

    Digital and behavioral training interventions have limited but emerging evidence.

    E‑therapy, biofeedback/neurofeedback, inhibition training: CBT‑based e‑interventions show small prevention effects; biofeedback/neurofeedback have preliminary data on physiological and brain‑activity changes but insufficient evidence for clinical benefit; food‑specific inhibition training shows feasibility in small proof‑of‑concept trials for BED but requires larger efficacy studies.

    Imaginal Exposure Response Prevention (I-ERP)

    Imaginal exposure programs have pilot‑level evidence only.

    I-ERP evidence: I‑ERP pilot studies in adolescents as an adjunct to inpatient care showed reductions in anxiety related to weight/shape but no significant change in eating‑disorder psychopathology and lacked randomized controls and follow‑up; further RCTs are needed.

    Music-based interventions

    Music-based interventions show small, heterogeneous positive findings but insufficient evidence for routine coverage.

    Music‑based interventions: Systematic reviews of music‑based interventions (16 small studies, n≈349) report improved mood regulation and reduced meal‑related distress but heterogeneity and small samples limit generalizability.

    rTMS / tDCS / DBS

    Neuromodulation evidence is mixed; most device‑based neuromodulation remains investigational for eating disorders.

    rTMS / tDCS / DBS evidence summary: Single‑session rTMS reduces food cravings; multi‑session rTMS and tDCS show promise for BN and BED but randomized trials are few and heterogeneous; tDCS combined with inhibitory control training showed reduced binge episodes in one phase II trial; TMS studies in anorexia report mixed effects on BMI and symptoms but remain experimental and should not replace nutritional rehabilitation or evidence‑based psychotherapy.

    Talking therapies (CBT, DBT, IPT, FB-IPT, schema therapy)

    Talking therapies are the evidence‑based core of psychological treatment for eating disorders.

    Talking therapies hierarchy: Evidence‑based hierarchy favors eating disorder–focused CBT as first‑line for bulimia nervosa and BED, with IPT and family‑based therapies appropriate in specific populations; DBT and other third‑wave therapies are alternatives when CBT is ineffective or not tolerated.

    Transcranial Magnetic Stimulation (TMS)

    TMS is experimental/adjunctive with mixed outcomes and safety considerations.

    TMS evidence and guidance: TMS studies include small randomized trials and observational studies with heterogeneous protocols, short follow‑up, mixed efficacy on symptoms and weight, and reported adverse events (headache, nausea, rare seizures); clinical guidelines state TMS is not an established treatment and should not supplant nutritional rehabilitation or evidence‑based psychotherapy.

    Neuromodulation (DBS, rTMS, etc.)

    Overarching neuromodulation stance:

    Neuromodulation (DBS, rTMS, etc.): Neuromodulation techniques (DBS, rTMS, tDCS, and related implanted neurostimulator procedures) are investigational for eating disorder indications given limited, heterogeneous evidence and safety concerns; requests for such interventions should be supported by patient‑level data, documented treatment‑refractory status, and prior authorization where applicable.

    Visit Limits, Duration, and Utilization Notes

    inv-105: No explicit visit limits specified for psychotherapy codes in this portion of the document.
    Psychotherapy visit limitsNo explicit visit limits are specified for psychotherapy CPT codes (e.g., 90791-90792, 90832-90838) in this portion of the document.
    ImplicationCoverage for psychotherapy is described as medically necessary when clinically appropriate; plan-level benefit limits may still apply per member policy documents.
    Related codesPsychotherapy and psychiatric evaluation CPT codes are listed among covered codes when selection criteria are met.
    inv-106: DBT app and self‑help interventions described but no formal visit/session limits provided in this segment.
    DBT app/self-help formatsDBT guided self-help and smartphone app formats are described (pilot RCTs show benefits) but the policy segment does not set formal visit or session limits for these interventions.
    Evidence caveatApp-based DBT trials had high dropout and variable engagement, and findings may not generalize to therapist-delivered DBT.
    Operational noteProgram delivery format (app vs therapist) may affect clinical documentation and coverage decisions; no payer-level session caps provided here.
    inv-107: Mandometer residential program average duration ~12 months noted (program-specific, not a payer limit).
    Program duration noteThe Mandometer residential program is described as averaging approximately 12 months in duration (program‑specific information; not a payer visit or stay limit).
    Policy implicationPolicy notes the program is controversial and lacks well-designed comparative trials; duration stated is descriptive and not an authorization of extended coverage.
    Coverage cautionAbsence of robust evidence may affect determinations of ongoing coverage or continued stay decisions for residential programs.

    Definitions and Terminology

    inv-66: Eating disorder diagnostic categories (ICD-10) — condensed definitional key-values
    ICD-10 category — ANF50.00 - F50.029 — Anorexia nervosa.
    ICD-10 category — BNF50.20 - F50.25 — Bulimia nervosa.
    Other categoriesF50.810 - F50.819 (BED); F50.82 (ARFID); R63.0 (Anorexia) — recognized diagnostic categories within policy.
    inv-67: Anorexia nervosa — definition/key diagnostic features
    Anorexia nervosa — core featuresRefusal to maintain minimally normal body weight (e.g., <85% expected), distorted body image, intense fear of weight gain; consider diagnosis with BMI ≤17.5 kg/m².
    EpidemiologyTypically begins in adolescence/young adulthood; ~90% of patients are female; lifetime mortality rate 15–20% in females.
    Typical complicationsMay cause amenorrhea, growth/failure-to-thrive in youth, and multi-system medical complications requiring multidisciplinary care.
    inv-68: Bulimia nervosa — definition/key diagnostic features
    Bulimia nervosa — core featuresRecurrent binge-eating with inappropriate compensatory behaviors (purging, restriction, excessive exercise) at least twice weekly for ≥3 months; patients often maintain normal weight.
    PrevalenceMore prevalent than anorexia in females (2–5%); lower mortality than AN but significant morbidity from electrolyte and GI disturbances.
    Clinical considerationSevere purging may lead to electrolyte imbalances and rare indications for hospitalization if life‑threatening complications occur.
    inv-70: Bright light therapy — definition
    DefinitionBright light therapy: noninvasive circadian-targeting intervention studied for binge‑eating and night‑eating presentations.
    Evidence noteSystematic review found 14 eligible studies with short-term improvements but emphasized need for placebo‑controlled and long-term trials.
    inv-71: Deep brain stimulation (DBS) — definition
    DefinitionDeep brain stimulation (DBS): surgically implanted electrical stimulation of specific brain targets investigated for treatment‑refractory anorexia nervosa.
    Evidence summaryPilot studies report some BMI and mood improvements in small cohorts but include serious adverse events and lack randomized controlled evidence.
    inv-82: Transcranial Magnetic Stimulation (TMS) — definition
    DefinitionTranscranial Magnetic Stimulation (TMS) is a noninvasive neuromodulatory technique targeting cortical areas (commonly dorsolateral prefrontal cortex) investigated experimentally for eating disorders.
    Policy guidanceTMS is described as experimental/adjunctive with mixed evidence; guidelines advise it should not replace nutritional rehabilitation or evidence-based psychotherapy.
    Evidence limitationsStudies limited by small sample sizes, heterogeneous protocols, and short follow-up; further randomized trials needed.

    Policy Revision History

    2026-08-04last_reviewLatest

    Policy last reviewed; review entry recorded in policy history.

    2001-06-11effective_date

    Policy originally became effective on this date.

    2026-08-04last_reviewLatest

    Policy last reviewed; references and bibliography updated as of this review date.

    2001-06-11effective_date

    Policy originally became effective on this date.